Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
NCT05208307
Recruiting
This phase II trial studies the effect of belantamab mafodotin, pomalidomide, and dexamethasone in treating patents with high-risk myeloma. Belantamab mafodotin is a monoclonal antibody, called belantamab, linked to a chemotherapy drug, called mafodotin. Belantamab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as BCMA receptors, and delivers mafodotin to kill them. Chemotherapy drugs, such as pomalidomide, work in different ways to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: Emory University/Winship Cancer Institute, Atlanta, Georgia
Conditions: Plasma Cell Myeloma
Register for Updates
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
NCT03937635
Recruiting
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +706 locations
Conditions: Smoldering Plasma Cell Myeloma
Register for Updates
Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel
NCT04862585
Completed
This phase II/III trial investigates the difference in rates of infusion hypersensitivity reaction in patients with breast cancer who are receiving paclitaxel alone or in combination with other cancer drugs which require parenteral rescue medication after stopping standard pre-medications (dexamethasone, diphenhydramine, famotidine/cimetidine/ranitidine), compared to continuing premedications. Paclitaxel is a drug used to treat breast cancer, ovarian cancer, and autoimmune deficiency syndrome (A... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2024
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Carcinoma, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
Register for Updates
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
NCT04508790
Recruiting
This phase II trial studies how well leflunomide, pomalidomide, and dexamethasone work for the treatment of multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Leflunomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with pomalidomide, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as dexamethasone, work... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Register for Updates
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
NCT04743661
Active Not Recruiting
A Phase 2 study investigating the addition of cRIT 131I-omburtamab to irinotecan, temozolomide, and bevacizumab for patients with recurrent medulloblastoma. A feasibility cohort is included to assess the feasibility of incorporating cRIT 131I-omburtamab for patients with recurrent ependymoma. Direct intraventricular delivery of radiolabeled tumor-specific antibodies may aid in both the detection and treatment of recurrent disease for these highly specific pediatric patients with recurrent tumor... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
08/02/2024
Locations: Children's Hospital Los Angeles, Los Angeles, California +2 locations
Conditions: Recurrent Medulloblastoma, Recurrent Ependymoma
Register for Updates
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
NCT03031730
Terminated
This phase I trial studies the side effects and best dose of MDM2 Inhibitor KRT-232 when given together with carfilzomib, lenalidomide, and dexamethasone in treating patient with multiple myeloma that has come back (relapsed) or has not responded to previous treatment (refractory). KRT-232 (AMG 232) may stop the growth of cancer cells by blocking a protein called MDM2 that is needed for cell growth. Lenalidomide help shrink or slow the growth of multiple myeloma. Drugs used in chemotherapy, such... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2024
Locations: University of California Davis Comprehensive Cancer Center, Sacramento, California +6 locations
Conditions: Plasmacytoma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Register for Updates
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
NCT03500445
Active Not Recruiting
The purpose of this study is to determine response rate after 8 cycles of D-KRd (daratumumab, carfilzomib, lenalidomide (Revlimid) and dexamethasone in patients with multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2024
Locations: The University of Chicago, Chicago, Illinois
Conditions: Myeloma, Multiple Myeloma
Register for Updates
Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma
NCT02969837
Active Not Recruiting
This study will be a multi-center, open-label, Phase 2 study where newly diagnosed Multiple Myeloma requiring systemic chemotherapy will be eligible for enrollment. A total of 55 subjects will be enrolled. Time to progression or death will be calculated from the date of first treatment on protocol until the date of disease progression or death from any cause. Patients can expect to participate between 12-24 cycles. The primary endpoint will be the rate of response by next generation gene sequenc... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2024
Locations: University of Chicago, Chicago, Illinois +2 locations
Conditions: Multiple Myeloma
Register for Updates
Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older
NCT02494882
Active Not Recruiting
The purpose of this study is to test the safety of a new combination of three oral drugs in Ph+ ALL. These drugs are dexamethasone, dasatinib, and ruxolitinib. All three drugs have been studied before in humans. This is a phase I study in which ruxolitinib dose will start low for the first patient together with dexamethasone plus dasatinib. If this dose does not cause a bad side effect, the ruxolitinib dose will slowly be made higher as new patients take part in the study. This will help the in... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/26/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Acute Lymphoblastic Leukemia
Register for Updates
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
NCT03110562
Completed
This Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study will compare the efficacy and health-related quality of life (HR-QoL) and assess the safety of selinexor plus bortezomib (Velcade) plus low-dose dexamethasone (SVd) versus bortezomib plus low-dose dexamethasone (Vd) in adult patients with RRMM who have received 1 to 3 prior anti-multiple myeloma (MM) regimens. Crossover from the Vd Arm to a treatment that includes selinexor (i.e., SVdX or SdX) will be al... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2024
Locations: Boca Raton Clinical Research (BRCR) Medical Center, Plantation, Florida +156 locations
Conditions: Multiple Myeloma
Register for Updates
Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy
NCT00871013
Active Not Recruiting
There have been four previous Total Therapy (TT1 through IIIB) studies for multiple myeloma at the MIRT from 1989 to present. Results have shown that participants treated on these studies had better outcomes (meaning they have lived longer and had better responses to treatment) when compared to individuals treated with standard chemotherapy. Past studies conducted at the MIRT have shown that participants presenting to MIRT who have already received treatment for myeloma tend to have shorter rem... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/24/2024
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Myeloma
Register for Updates
The Effects of IV vs Oral Dexamethasone on Postoperative Nausea, Vomiting, and Pain
NCT04563494
Completed
The hypothesis being tested in this study is that perioperative oral administration of dexamethasone, when compared to intravenous (IV) administration, offers a similar reduction in postoperative nausea and vomiting (PONV), and reduction in postoperative pain in pediatric patients undergoing tonsillectomy with or without adenoidectomy and/or tympanostomy tube placement. The specific aim of this study is to demonstrate non-inferiority of oral dexamethasone when compared to IV dexamethasone, given... Read More
Gender:
ALL
Ages:
Between 3 years and 7 years
Trial Updated:
07/18/2024
Locations: Children's Hospital of Colorado, Aurora, Colorado
Conditions: Nausea and Vomiting, Postoperative
Register for Updates